[go: up one dir, main page]

MX2009008338A - Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. - Google Patents

Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.

Info

Publication number
MX2009008338A
MX2009008338A MX2009008338A MX2009008338A MX2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A
Authority
MX
Mexico
Prior art keywords
conditions
sodium channel
mediated diseases
compounds useful
treating sodium
Prior art date
Application number
MX2009008338A
Other languages
English (en)
Inventor
Rajender Kamboj
Shifeng Liu
Sultan Chowdhury
Jianmin Fu
Qi Jia
Jianyu Sun
Mark Wood
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2009008338A publication Critical patent/MX2009008338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de piridopirimidinona de la fórmula (I): (ver fórmula I) en donde n, R1, R2 y R3 son como se definen en la presente, como uno de sus estereoisómeros, enantiómeros, tautómeros, o una de sus mezclas; o una de sus sales, solvatos o profármacos farmacéuticamente aceptables, de utilidad para el tratamiento y/o de la prevención de enfermedades o condiciones patológicas mediadas por el canal de sodio, como dolor.
MX2009008338A 2007-02-05 2008-02-05 Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. MX2009008338A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88825307P 2007-02-05 2007-02-05
US91212207P 2007-04-16 2007-04-16
PCT/US2008/053075 WO2008097991A1 (en) 2007-02-05 2008-02-05 Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

Publications (1)

Publication Number Publication Date
MX2009008338A true MX2009008338A (es) 2009-08-12

Family

ID=39420569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008338A MX2009008338A (es) 2007-02-05 2008-02-05 Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.

Country Status (12)

Country Link
US (1) US20080194616A1 (es)
EP (1) EP2079737A1 (es)
JP (1) JP2010518026A (es)
AR (1) AR065194A1 (es)
AU (1) AU2008213836A1 (es)
BR (1) BRPI0807351A2 (es)
CA (1) CA2677493A1 (es)
CL (1) CL2008000369A1 (es)
MX (1) MX2009008338A (es)
RU (1) RU2009133336A (es)
TW (1) TW200838539A (es)
WO (1) WO2008097991A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) * 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
CN101610765A (zh) * 2006-12-18 2009-12-23 卡多兹公司 用于治疗炎症的新组合物
WO2008075028A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
GEP20125574B (en) * 2008-01-11 2012-07-10 Glenmark Pharmaceuticals Sa Fused pyrimidine derivatives as trpv3 modulators
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
AU2009235276A1 (en) * 2008-04-07 2009-10-15 Cardoz Ab New combination for use in the treatment of inflammatory disorders
US8119647B2 (en) * 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CN104024251B (zh) 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
WO2013115884A2 (en) * 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2878478A1 (en) * 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
JP6096370B2 (ja) 2013-03-14 2017-03-15 ジェネンテック， インコーポレイテッド 置換トリアゾロピリジンとその使用方法
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
JP6445565B2 (ja) * 2013-09-10 2018-12-26 クロモセル コーポレイション とう痛及び糖尿病の治療用ナトリウムチャネル調節物質
EA201691085A1 (ru) 2013-11-27 2017-02-28 Дженентек, Инк. Замещенные бензамиды и способы их применения
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
JP6847851B2 (ja) * 2015-04-15 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
US9902696B2 (en) 2015-06-18 2018-02-27 Cephalon, Inc. 1,4-substituted piperidine derivatives
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
RU2018115718A (ru) 2015-09-28 2019-10-28 Дженентек, Инк. Терапевтические соединения и способы их применения
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
JP2021514980A (ja) 2018-02-26 2021-06-17 ジェネンテック， インコーポレイテッド 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
KR20210018328A (ko) 2018-06-01 2021-02-17 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법
JP2021526900A (ja) * 2018-06-05 2021-10-11 インカーダ セラピューティクス， インコーポレイテッド エアロゾルを用いるブルガダ症候群の診断方法
EP4065579A1 (en) * 2019-11-25 2022-10-05 Amgen Inc. Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
CN110818709B (zh) * 2019-11-28 2022-09-02 成都大学 一种co2参与下合成嘧啶酮类化合物的方法
CN113292557B (zh) * 2021-05-31 2022-02-11 贵州大学 一种含吲哚单元的吡啶并嘧啶酮类介离子衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63112566A (ja) * 1986-10-28 1988-05-17 Nissan Chem Ind Ltd ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤
US20070213338A1 (en) * 2003-10-21 2007-09-13 Lebsack Alec D Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US7799795B2 (en) * 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
US7939537B2 (en) * 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
EP1818058A3 (en) * 2006-02-13 2007-11-07 Astion Pharma A/S Treatment of mmp-mediated dermatological diseases with pemirolast

Also Published As

Publication number Publication date
CA2677493A1 (en) 2008-08-14
JP2010518026A (ja) 2010-05-27
CL2008000369A1 (es) 2008-04-18
TW200838539A (en) 2008-10-01
WO2008097991A1 (en) 2008-08-14
RU2009133336A (ru) 2011-03-20
AU2008213836A1 (en) 2008-08-14
US20080194616A1 (en) 2008-08-14
AR065194A1 (es) 2009-05-20
BRPI0807351A2 (pt) 2014-05-20
EP2079737A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
JO3032B1 (ar) مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
MY145694A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
MY144968A (en) Spiro-oxindole compounds and their uses as therapeutic agents
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
TW200716596A (en) Substituted amide derivatives and methods of use
WO2008046084A3 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
PH12012500726A1 (en) Synthetic methods for spiro-oxindole compounds
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2008109856A3 (en) Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives